Adrenomedullin(27-52) inhibits vascular calcification in rats.
Adrenomedullin (ADM) has the vasodilatory properties and involves in the pathogenesis of vascular calcification. ADM could be degraded into more than six fragments in the body, including ADM(27-52), and we suppose the degrading fragments from ADM do the same bioactivities as derived peptides from pro-adrenomedullin. The present study carries forward by assessing the effects on vascular calcification of the systemic administration of ADM(27-52). The rat vascular calcific model was replicated with vitamin D3 and nicotine. ADM or/and ADM(27-52) were systemically administrated with mini-osmotic pump beginning at seventh day after the model replication for 25 days. Vascular calcific nodules histomorphometry, vascular calcium content, vascular calcium uptake, alkaline phosphatase activity, and osteopontin-mRNA quantification in aorta were assessed. ADM limited 40.2% vascular calcific nodules (P<0.01), did not effect on calcium content (P>0.05), reduced 44.4% calcium uptake (P<0.01), lowered 21.1% alkaline phosphatase activity (P<0.01), and regulated 40.9% downwards osteopontin-mRNA expression (P<0.01) in the aorta of rats with vascular calcification. ADM(27-52) receded 32.0% vascular calcific nodules (P<0.01), taken from 55.5% calcium content (P<0.01), did not affect calcium uptake (P>0.05), inhibited 22.5% alkaline phosphatase activity (P<0.01), and restrained 21.9% osteopontin-mRNA expression (P<0.01) in the aorta of rats with vascular calcification. Both of ADM and ADM(27-52) did interact on vascular calcification each other. ADM could partially antagonize the effects of ADM(27-52) in taking from calcium content (17.5%, P<0.01) and in receding vascular calcific nodules (18.6%, P<0.01). ADM could obviously enhance the action of ADM(27-52) in inhibiting alkaline phosphatase activity (14.4%, P<0.01) and in reducing calcium uptake (11.4%, P<0.01). ADM(27-52) could partially antagonize the effects of ADM on regulating downwards osteopontin-mRNA expression (17.0%, P<0.01). It is concluded that ADM(27-52) derived from ADM acts as an inhibitory agent on vascular calcification, with special mechanisms different from ADM derived from ADM progenitor molecule.
Cai
Da-Yong
DY
Institute of Cardiovascular Disease, Peking University First Hospital, Beijing 100034, China.
Yu
Fang
F
Jiang
Wei
W
Jiang
Hong-Feng
HF
Pan
Chun-Shui
CS
Qi
Yong-Feng
YF
Chang
Lin
L
Zhao
Jin
J
Yang
Jin-Hui
JH
Zhu
Ming-Jia
MJ
Jia
Yue-Xia
YX
Geng
Bin
B
Ma
Tie-Min
TM
Pang
Yong-Zheng
YZ
Tang
Chao-Shu
CS
D053607:Adrenomedullin; D000818:Animals; D001013:Aorta, Thoracic / Q000378:metabolism* / Q000473:pathology; D002114:Calcinosis / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D002762:Cholecalciferol / Q000633:toxicity; D008297:Male; D009538:Nicotine / Q000633:toxicity; D018722:Nicotinic Agonists / Q000633:toxicity; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley
D018722:Nicotinic Agonists; D010446:Peptide Fragments; C432594:adrenomedullin (27-52); D053607:Adrenomedullin; D002762:Cholecalciferol; D009538:Nicotine